This Core serves as the point of entry for human subjects into the project. This Core is responsible for the clinical evaluations of patients with suspected HD, presymptomatic evaluations of individuals at risk for HD, and evaluation of patients with HDlike phenotypes. This Core maintains an extensive computerized database which is unique in its scope, duration, and number of subjects. This Core includes a weekly research clinic, in which new evaluations are performed, with subjects followed annually. This Core also contains the Longitudinal Core Study, in which a subset of the clinic population is examined and given a more extensive battery and a biannual MRI. This Core has also been responsible for the highly successful recruitment of subjects for clinical trials. The goals of this Core for this submission are to continue to evaluate affected, at risk, and HDlike subjects and recruit them into longitudinal followup, to continue to generate a body of longitudinal data on these subjects from the preclinical period all the way to death, to continue to provide more extensive testing on a subset of the cohort in the Longitudinal Core Study (which will also serve as the primary reservoir of subjects for therapeutic trials), and to develop new methods of assessment which are particularly sensitive to early HD and capable of distinguishing presymptomatic gene carriers from controls.

Project Start
1980-07-01
Project End
2006-04-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
21
Fiscal Year
2001
Total Cost
$172,411
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Faria, Andreia V; Ratnanather, J Tilak; Tward, Daniel J et al. (2016) Linking white matter and deep gray matter alterations in premanifest Huntington disease. Neuroimage Clin 11:450-460
Krause, Amanda; Mitchell, Claire; Essop, Fahmida et al. (2015) Junctophilin 3 (JPH3) expansion mutations causing Huntington disease like 2 (HDL2) are common in South African patients with African ancestry and a Huntington disease phenotype. Am J Med Genet B Neuropsychiatr Genet 168:573-85
Ross, Christopher A; Pantelyat, Alex; Kogan, Jane et al. (2014) Determinants of functional disability in Huntington's disease: role of cognitive and motor dysfunction. Mov Disord 29:1351-8
Hua, Jun; Unschuld, Paul G; Margolis, Russell L et al. (2014) Elevated arteriolar cerebral blood volume in prodromal Huntington's disease. Mov Disord 29:396-401
Unschuld, Paul G; Liu, Xinyang; Shanahan, Megan et al. (2013) Prefrontal executive function associated coupling relates to Huntington's disease stage. Cortex 49:2661-73
Unschuld, Paul G; Edden, Richard A E; Carass, Aaron et al. (2012) Brain metabolite alterations and cognitive dysfunction in early Huntington's disease. Mov Disord 27:895-902
Guo, Zhihong; Rudow, Gay; Pletnikova, Olga et al. (2012) Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease. Mov Disord 27:1379-86
Fu, Jinrong; Jin, Jing; Cichewicz, Robert H et al. (2012) trans-(-)-?-Viniferin increases mitochondrial sirtuin 3 (SIRT3), activates AMP-activated protein kinase (AMPK), and protects cells in models of Huntington Disease. J Biol Chem 287:24460-72
Rosenblatt, Adam; Kumar, Brahma V; Mo, Alisa et al. (2012) Age, CAG repeat length, and clinical progression in Huntington's disease. Mov Disord 27:272-6
Ratovitski, Tamara; Chighladze, Ekaterine; Arbez, Nicolas et al. (2012) Huntingtin protein interactions altered by polyglutamine expansion as determined by quantitative proteomic analysis. Cell Cycle 11:2006-21

Showing the most recent 10 out of 55 publications